Why Levothyroxine Stops Working (The Conversion Problem Nobody Tests)

Most people think hypothyroidism is simple: your thyroid is underactive, so you take a pill that replaces what your thyroid should be making, your TSH comes back normal, and you're treated. That model works for a lot of people. But for a meaningful number of patients, it doesn't, and the reason why lives in a part of the system that most doctors never check.

To understand why, you need the full picture first.

Your thyroid produces two hormones: T4 and T3. T4 is the storage form, something like a precursor molecule that the body holds in reserve. T3 is the active form, the one that actually enters your cells, binds to receptors, and drives the downstream effects you associate with thyroid function: energy, metabolism, temperature regulation, mood, cognition. The critical detail is that your thyroid itself only produces about 20% of the T3 circulating in your body at any given time. The other 80% has to be manufactured elsewhere, through a conversion process that happens primarily in your liver, your kidneys, and your gut.

That conversion is carried out by a family of enzymes called deiodinases, which are proteins that physically remove an iodine atom from T4 to produce T3. The most relevant ones here are called type 1 and type 2 deiodinase, referred to as DIO1 and DIO2. These enzymes are what chemists call selenoproteins, meaning they require the mineral selenium to function. Without adequate selenium, the enzymes don't work efficiently, T4 accumulates, and T3 output drops even if T4 levels look completely normal on a lab panel.

This is where levothyroxine enters the picture.

Levothyroxine is synthetic T4. When a doctor prescribes it for hypothyroidism, the entire therapeutic model rests on an assumption: that the patient's body will take that T4 and convert it into the T3 their cells need. The prescription is essentially outsourcing the 80% to the patient's own conversion machinery.

The problem is that nobody usually checks whether the conversion machinery is working.

What gets checked instead is TSH, something called thyroid stimulating hormone, which is a signal released by a small gland at the base of your brain called the pituitary. The pituitary monitors T4 levels and adjusts TSH output accordingly. When T4 is low, TSH rises to stimulate the thyroid to produce more. When T4 is adequate, TSH falls. So when a doctor doses levothyroxine until TSH is in normal range, they are confirming that the pituitary is seeing enough T4. That is all they are confirming.

TSH tells you nothing about whether T4 is being converted into T3 in peripheral tissues.

Research has started to quantify the gap. Studies looking at patients on levothyroxine monotherapy with normal TSH have found that their T3 to T4 ratios run 15 to 20% lower than those of people with naturally functioning thyroid glands. In a healthy thyroid, the gland secretes both T4 and T3 directly, contributing to that T3 pool in a way that levothyroxine does not replicate. Replace the gland with T4-only medication, even perfectly dosed, and you may be maintaining the pituitary signal while leaving peripheral T3 lower than it would have been before the thyroid failed. One large patient survey found that up to 40% of levothyroxine-treated patients with normal TSH were still reporting significant symptoms.

Several things can impair conversion further and compound this problem.

Chronic inflammation is one of them. The deiodinase enzymes appear to be downregulated under inflammatory conditions, meaning the body produces less of them or reduces their activity when systemic inflammation is elevated. For people with Hashimoto's disease, which is an autoimmune condition that attacks the thyroid tissue itself, this creates a compounding problem: the autoimmune inflammation directly reduces the thyroid's output of that 20% T3, and simultaneously impairs the peripheral conversion responsible for the other 80%. Treating TSH to normal range in this context may still leave the patient in a state of relative T3 deficiency.

Liver dysfunction is another variable. Because the liver is one of the primary sites of T4 to T3 conversion, anything that compromises liver function, whether that is fatty liver disease, elevated liver enzymes, or chronic alcohol use, can reduce the efficiency of that conversion process.

Gut dysbiosis, meaning an imbalance in the microbial populations of the gut, appears to matter as well, though the mechanism here is less fully characterized. Some deiodinase activity occurs in gut tissue, and the gut microbiome appears to influence thyroid hormone metabolism through pathways that are still being studied. This is one area where the research is more preliminary and the clinical implications are less clearly established.

Then there is the genetic layer.

Between 12 and 36% of people carry a variant in the gene that codes for the type 2 deiodinase enzyme, the DIO2 gene. This variant reduces the efficiency of T4 to T3 conversion at the cellular level. Studies have found that people carrying this variant report lower psychological well-being on T4 monotherapy compared to people without the variant, and that the same patients show improvement when T3 is added to the regimen. This means that for a substantial fraction of the population, the conversion deficit is not a consequence of inflammation or nutrient deficiency or liver function. It is written into their biology from birth.

So what should you actually do with this information.

The first step is straightforward: ask your doctor to run free T3 alongside TSH. Free T3 measures the unbound, bioavailable T3 in your blood and tells you whether conversion is producing adequate active hormone. TSH alone cannot answer that question.

If your free T3 is low or in the low normal range while you are still symptomatic, selenium is worth discussing with your provider. The standard dose studied in thyroid research is 200 micrograms per day, typically as selenomethionine. The research here is not definitive, but the mechanism is direct: selenium is a structural requirement for the enzymes doing the conversion. If selenium is limiting the enzyme output, replacing it addresses the root constraint.

For patients who have optimized selenium, ruled out liver and inflammatory contributors, and still have low T3 and persistent symptoms, a conversation about combination T4 plus T3 therapy becomes worth having. This is not the standard of care and carries its own considerations, but for patients with confirmed DIO2 variants or persistently poor conversion, it represents the logical next step in the clinical reasoning.

The deeper issue here is not really about medication. It is about what a normal lab value actually means.

A normal TSH means the pituitary is satisfied. It does not mean your cells are receiving adequate T3. It does not mean conversion is working. It does not mean the person sitting in the exam room is well. The lab value and the patient's experience have been treated as the same thing for decades, and for a significant number of patients, they are not. The test that gets run is the one that answers the easiest question, not the one that maps to how the patient actually feels.

Testing for what you're treating is not optional. It's the whole point of testing.

---

References

1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;11610:2571-2579. PMID: 17016550. Source
2. Endotext NCBI Bookshelf. Thyroid Hormone Synthesis and Secretion: "The thyroid gland produces approximately 20% of total daily T3 production, with the remaining 80% arising from peripheral deiodination of T4." Source
3. Salvatore D, Porcelli T, Ettleson MD, Bianco AC. The relevance of T3 in the management of hypothyroidism. Lancet Diabetes Endocrinol. 2022;10(5):366-372. DOI: 10.1016/S2213-8587(22)00004-3.
4. Peterson SJ, Cappola AR, Castro MR, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2019;295:707-721. PMID: 29620972. Source
5. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy. JCEM. 2009;945:1623-1629. PMID: 19190113. Source
6. Kobayashi R, Hasegawa Y, Kawaguchi T, et al. Thyroid function in patients with selenium deficiency exhibits high free T4 to T3 ratio. Clin Pediatr Endocrinol. 2021;30(1):19-26. DOI: 10.1297/cpe.30.19.
7. Ventura M, Melo M, Carrilho F. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol. 2017;2017:1297658. PMID: 28255299. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness